RTI Biologics Posts 11% Higher Revenues in Third Quarter, a RecordWritten by Staff | October 29, 2009
RTI Biologics, maker of orthopedic and other biologic implants, posted record revenues of $42.8 million for the third quarter, an 11 percent increase over the same period last year, according to a release from RTI Biologics.
Domestic revenues were $37.4 million for the third quarter and $105.4 million for the first nine months of 2009, both representing increases of 12 percent over the same periods the year before.
Third-quarter revenues reflect the launch of four new orthopedic implants and revenue for the first nine months reflects new revenues from Tutogen, which merged with RTI.
Read the release on RTI Biologics third-quarter revenue.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.